Skip to main content Accessibility help
Hostname: page-component-8bbf57454-9s44l Total loading time: 0.321 Render date: 2022-01-22T01:09:19.440Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Inflammatory bowel disease and the gut microbiota

Published online by Cambridge University Press:  21 June 2021

Nan Wu
Microbiome Research Centre, St George and Sutherland Clinical School, University of New South Wales, Sydney, New South Wales, Australia
Cassandra Mah
Microbiome Research Centre, St George and Sutherland Clinical School, University of New South Wales, Sydney, New South Wales, Australia
Sabrina Koentgen
Microbiome Research Centre, St George and Sutherland Clinical School, University of New South Wales, Sydney, New South Wales, Australia
Leo Zhang
Microbiome Research Centre, St George and Sutherland Clinical School, University of New South Wales, Sydney, New South Wales, Australia
Michael C. Grimm
Microbiome Research Centre, St George and Sutherland Clinical School, University of New South Wales, Sydney, New South Wales, Australia
Emad El-Omar
Microbiome Research Centre, St George and Sutherland Clinical School, University of New South Wales, Sydney, New South Wales, Australia
Georgina L. Hold*
Microbiome Research Centre, St George and Sutherland Clinical School, University of New South Wales, Sydney, New South Wales, Australia
*Corresponding author: Georgina L. Hold, email


Inflammatory bowel disease (IBD) is a group of immune-mediated disorders characterised by a chronic, relapsing-remitting inflammation predominantly affecting the gastrointestinal tract. IBD is incurable, affecting people in their most productive years. IBD is historically seen as a disease of Westernised nations although in recent times other countries have seen an exponential rise in cases. Although the exact pathogenesis remains unclear, evidence suggests that microbiota changes play a critical role in IBD pathogenesis. Over the past two decades, IBD has become one of the most studied human conditions linked to the gut microbiota. However, deciphering the intricate link between the gut microbiota and therapeutic efficacy remains elusive. This review will summarise the current evidence relating to the gut microbiota and its involvement in IBD pathogenesis as well as the impact of IBD treatments including pharmaceutical-, nutraceutical- and microbial-focused regimens on the gut microbiota.

Conference on ‘Gut microbiome and health’
Copyright © The Author(s), 2021. Published by Cambridge University Press on behalf of The Nutrition Society

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)


Equal contribution.


Halfvarson, J, Brislawn, CJ, Lamendella, R et al. (2017) Dynamics of the human gut microbiome in inflammatory bowel disease. Nat Microbiol 2, 17004.Google ScholarPubMed
Tremaine, WJ (2011) Diagnosis and treatment of indeterminate colitis. Gastroenterol Hepatol (N Y) 7, 826828.Google ScholarPubMed
Strong, S, Koltun, W, Hyman, N et al. (2007) Standards Practice Task Force of The American Society of C, Rectal S. Practice parameters for the surgical management of Crohn's disease. Dis Colon Rectum 50, 17351746.CrossRefGoogle Scholar
Gardiner, KR & Dasari, BV (2007) Operative management of small bowel Crohn's disease. Surg Clin North Am 87, 587610.CrossRefGoogle ScholarPubMed
Chen, JH, Andrews, JM, Kariyawasam, V et al. (2016) Acute severe ulcerative colitis – evidence-based consensus statements. Aliment Pharmacol Ther 44, 127144.CrossRefGoogle ScholarPubMed
Dinesen, LC, Walsh, AJ, Protic, MN et al. (2010) The pattern and outcome of acute severe colitis. J Crohns Colitis 4, 431437.CrossRefGoogle ScholarPubMed
Rutter, MD, Saunders, BP, Wilkinson, KH et al. (2006) Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 130, 10301038.CrossRefGoogle ScholarPubMed
Choi, CR, Al Bakir, I, Ding, NJ et al. (2019) Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study. Gut 68, 414422.CrossRefGoogle Scholar
Lambert, JE, Parnell, JA, Han, J et al. (2014) Evaluation of yellow pea fibre supplementation on weight loss and the gut microbiota: a randomized controlled trial. BMC Gastroenterol 14, 69.CrossRefGoogle ScholarPubMed
Harbord, M, Annese, V, Vavricka, SR et al. (2016) The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis 10, 239254.CrossRefGoogle ScholarPubMed
Chang, JT (2020) Pathophysiology of inflammatory bowel diseases. N Engl J Med 383, 26522664.CrossRefGoogle ScholarPubMed
Yilmaz, B, Juillerat, P, Oyas, O et al. (2019) Microbial network disturbances in relapsing refractory Crohn's disease. Nat Med 25, 323336.CrossRefGoogle ScholarPubMed
Jostins, L, Ripke, S, Weersma, RK et al. (2012) Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119124.CrossRefGoogle ScholarPubMed
Nasser, J, Bergman, DT, Fulco, CP et al. (2021) Genome-wide enhancer maps link risk variants to disease genes. Nature 593(7858), 238243.CrossRefGoogle ScholarPubMed
Maier, L, Pruteanu, M, Kuhn, M et al. (2018) Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555, 623628.CrossRefGoogle ScholarPubMed
Savage, N (2020) The complex relationship between drugs and the microbiome. Nature 577, S10S11.CrossRefGoogle ScholarPubMed
Turner, J (2010) The gastrointestinal tract. In Robbins and Cotran Pathologic Basis of Disease [Kumar, V, Abbas, A and et al. , editors]. Philadelphia: Saunders Elsevier.Google Scholar
Ni, J, Wu, GD, Albenberg, L et al. (2017) Gut microbiota and IBD: causation or correlation? Nat Rev Gastroenterol Hepatol 14, 573584.CrossRefGoogle ScholarPubMed
Dave, M, Higgins, PD, Middha, S et al. (2012) The human gut microbiome: current knowledge, challenges, and future directions. Transl Res 160, 246257.CrossRefGoogle Scholar
Brandtzaeg, P (2009) Mucosal immunity: induction, dissemination, and effector functions. Scand J Immunol 70, 505515.CrossRefGoogle ScholarPubMed
Franzosa, EA, Sirota-Madi, A, Avila-Pacheco, J et al. (2019) Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol 4, 293305.CrossRefGoogle ScholarPubMed
Sellon, RK, Tonkonogy, S, Schultz, M et al. (1998) Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 66, 52245231.CrossRefGoogle ScholarPubMed
Balish, E & Warner, T (2002) Enterococcus faecalis induces inflammatory bowel disease in interleukin-10 knockout mice. Am J Pathol 160, 22532257.CrossRefGoogle ScholarPubMed
Chiaro, TR, Soto, R, Zac Stephens, W et al. (2017) A member of the gut mycobiota modulates host purine metabolism exacerbating colitis in mice. Sci Transl Med 9(380), eaaf9044.CrossRefGoogle ScholarPubMed
Ambrose, NS, Allan, RN, Keighley, MR et al. (1985) Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. A prospective randomized study. Dis Colon Rectum 28, 8185.CrossRefGoogle ScholarPubMed
Segal, JP, Oke, S, Hold, GL et al. (2018) Systematic review: ileoanal pouch microbiota in health and disease. Aliment Pharmacol Ther 47, 466477.CrossRefGoogle ScholarPubMed
Rutgeerts, P (1994) Recurrence of Crohn's disease in the neoterminal ileum after ileal resection: is prevention therapy possible? Neth J Med 45, 6064.Google ScholarPubMed
D'Haens, GR, Geboes, K, Peeters, M et al. (1998) Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 114, 262267.CrossRefGoogle ScholarPubMed
Mukhopadhya, I, Hansen, R, El-Omar, EM et al. (2012) IBD – what role do Proteobacteria play? Nat Rev Gastroenterol Hepatol 9, 219230.CrossRefGoogle ScholarPubMed
Thomson, JM, Hansen, R, Berry, SH et al. (2011) Enterohepatic helicobacter in ulcerative colitis: potential pathogenic entities? PLoS One 6, e17184.CrossRefGoogle ScholarPubMed
Mukhopadhya, I, Thomson, JM, Hansen, R et al. (2011) Detection of Campylobacter concisus and other Campylobacter species in colonic biopsies from adults with ulcerative colitis. PLoS One 6, e21490.CrossRefGoogle ScholarPubMed
Kaakoush, NO, Holmes, J, Octavia, S et al. (2010) Detection of Helicobacteraceae in intestinal biopsies of children with Crohn's disease. Helicobacter 15, 549557.CrossRefGoogle ScholarPubMed
Imhann, F, Vich Vila, A, Bonder, MJ et al. (2018) Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. Gut 67, 108119.CrossRefGoogle ScholarPubMed
Morgan, XC, Tickle, TL, Sokol, H et al. (2012) Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 13, R79.CrossRefGoogle ScholarPubMed
Haberman, Y, Tickle, TL, Dexheimer, PJ et al. (2014) Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. J Clin Invest 124, 36173633.CrossRefGoogle ScholarPubMed
Pascal, V, Pozuelo, M, Borruel, N et al. (2017) A microbial signature for Crohn's disease. Gut 66, 813822.CrossRefGoogle ScholarPubMed
Costello, EK, Lauber, CL, Hamady, M et al. (2009) Bacterial community variation in human body habitats across space and time. Science 326, 16941697.CrossRefGoogle ScholarPubMed
Kostic, AD, Xavier, RJ & Gevers, D (2014) The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 146, 14891499.CrossRefGoogle ScholarPubMed
Zhou, Y, Xu, ZZ, He, Y et al. (2018) Gut microbiota offers universal biomarkers across ethnicity in inflammatory bowel disease diagnosis and infliximab response prediction. mSystems 3(1), e0018817.CrossRefGoogle ScholarPubMed
Dorrestein, PC, Mazmanian, SK & Knight, R (2014) Finding the missing links among metabolites, microbes, and the host. Immunity 40, 824832.CrossRefGoogle ScholarPubMed
McHardy, IH, Goudarzi, M, Tong, M et al. (2013) Integrative analysis of the microbiome and metabolome of the human intestinal mucosal surface reveals exquisite inter-relationships. Microbiome 1, 17.CrossRefGoogle ScholarPubMed
Ananthakrishnan, AN, Luo, C, Yajnik, V et al. (2017) Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases. Cell Host Microbe 21, 603610 e603.CrossRefGoogle ScholarPubMed
Haiser, HJ, Gootenberg, DB, Chatman, K et al. (2013) Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science 341, 295298.CrossRefGoogle ScholarPubMed
Sivan, A, Corrales, L, Hubert, N et al. (2015) Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350, 10841089.CrossRefGoogle ScholarPubMed
Vetizou, M, Pitt, JM, Daillere, R et al. (2015) Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 10791084.CrossRefGoogle ScholarPubMed
Cross, RK & Farraye, FA (2018) IBD management: state of the art in 2018. Gastroenterol Hepatol (N Y) 14, 6.Google Scholar
Aloi, M, Nuti, F, Stronati, L et al. (2014) Advances in the medical management of paediatric IBD. Nat Rev Gastroenterol Hepatol 11, 99108.CrossRefGoogle ScholarPubMed
D'Haens, G, Baert, F, van Assche, G et al. (2008) Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371, 660667.CrossRefGoogle ScholarPubMed
Colombel, JF, Sands, BE, Rutgeerts, P et al. (2017) The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut 66, 839851.CrossRefGoogle ScholarPubMed
Colombel, JF, Narula, N & Peyrin-Biroulet, L (2017) Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology 152, 351361 e355.CrossRefGoogle ScholarPubMed
Lichtenstein, GR, Hanauer, SB, Sandborn, WJ et al. (2009) Management of Crohn's disease in adults. Am J Gastroenterol 104, 465483; quiz 464, 484.CrossRefGoogle ScholarPubMed
Khanna, R, Bressler, B, Levesque, BG et al. (2015) Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet 386, 18251834.CrossRefGoogle ScholarPubMed
Punchard, NA, Greenfield, SM & Thompson, RP (1992) Mechanism of action of 5-arninosalicylic acid. Mediators Inflamm 1, 151165.CrossRefGoogle ScholarPubMed
Xu, J, Chen, N, Wu, Z et al. (2018) 5-Aminosalicylic acid alters the gut bacterial microbiota in patients with ulcerative colitis. Front Microbiol 9, 1274.CrossRefGoogle ScholarPubMed
Schirmer, M, Denson, L, Vlamakis, H et al. (2018) Compositional and temporal changes in the gut microbiome of pediatric ulcerative colitis patients are linked to disease course. Cell Host Microbe 24, 600610 e604.CrossRefGoogle ScholarPubMed
Parameswaran, N & Patial, S (2010) Tumor necrosis factor-alpha signaling in macrophages. Crit Rev Eukaryot Gene Expr 20, 87103.CrossRefGoogle ScholarPubMed
Stevens, SR & Chang, TH (2006) History of development of TNF inhibitors. In TNF-alpha Inhibitors, pp. 922 [Weinberg, JM and Buchholz, R, editors]. Basel: Birkhäuser Basel.CrossRefGoogle Scholar
Lewis, JD, Chen, EZ, Baldassano, RN et al. (2015) Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn's disease. Cell Host Microbe 18, 489500.CrossRefGoogle ScholarPubMed
Wang, Y, Gao, X, Ghozlane, A et al. (2018) Characteristics of faecal microbiota in paediatric Crohn's disease and their dynamic changes during infliximab therapy. J Crohns Colitis 12, 337346.CrossRefGoogle ScholarPubMed
Magnusson, MK, Strid, H, Sapnara, M et al. (2016) Anti-TNF therapy response in patients with ulcerative colitis is associated with colonic antimicrobial peptide expression and microbiota composition. J Crohns Colitis 10, 943952.CrossRefGoogle ScholarPubMed
Kolho, KL & Sipponen, T (2014) The long-term outcome of anti-tumor necrosis factor-alpha therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease. Scand J Gastroenterol 49, 434441.CrossRefGoogle ScholarPubMed
Kolho, KL, Korpela, K, Jaakkola, T et al. (2015) Fecal microbiota in pediatric inflammatory bowel disease and its relation to inflammation. Am J Gastroenterol 110, 921930.CrossRefGoogle ScholarPubMed
Huttenhower, C, Kostic, AD & Xavier, RJ (2014) Inflammatory bowel disease as a model for translating the microbiome. Immunity 40, 843854.CrossRefGoogle ScholarPubMed
Rajca, S, Grondin, V, Louis, E et al. (2014) Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease. Inflamm Bowel Dis 20, 978986.Google ScholarPubMed
Rietdijk, ST & D'Haens, GR (2013) Recent developments in the treatment of inflammatory bowel disease. J Dig Dis 14, 282287.CrossRefGoogle ScholarPubMed
Feagan, BG, Sandborn, WJ, Gasink, C et al. (2016) Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 375, 19461960.CrossRefGoogle ScholarPubMed
Sandborn, WJ, Gasink, C, Gao, LL et al. (2012) Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 367, 15191528.CrossRefGoogle ScholarPubMed
Doherty, MK, Ding, T, Koumpouras, C et al. (2018) Fecal microbiota signatures are associated with response to ustekinumab therapy among Crohn's disease patients. mBio 9, e02120–e02117.CrossRefGoogle ScholarPubMed
Graham, TO & Kandil, HM (2002) Nutritional factors in inflammatory bowel disease. Gastroenterol Clin North Am 31, 203218.CrossRefGoogle ScholarPubMed
Muller, JM, Keller, HW, Erasmi, H et al. (1983) Total parenteral nutrition as the sole therapy in Crohn's disease – a prospective study. Br J Surg 70, 4043.CrossRefGoogle ScholarPubMed
Gonzalez-Huix, F, Fernandez-Banares, F, Esteve-Comas, M et al. (1993) Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am J Gastroenterol 88, 227232.Google ScholarPubMed
Caprilli, R, Gassull, MA, Escher, JC et al. (2006) European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 55(Suppl. 1), i36i58.CrossRefGoogle ScholarPubMed
Sandhu, BK, Fell, JM, Beattie, RM et al. (2010) Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. J Pediatr Gastroenterol Nutr 50(Suppl. 1), S113.CrossRefGoogle ScholarPubMed
Zachos, M, Tondeur, M & Griffiths, AM (2007) Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev 3, CD000542.Google Scholar
Lionetti, P, Callegari, ML, Ferrari, S et al. (2005) Enteral nutrition and microflora in pediatric Crohn's disease. JPEN: J Parenter Enteral Nutr 29, S173S175; discussion S175–178, S184–178.CrossRefGoogle ScholarPubMed
Leach, ST, Mitchell, HM, Eng, WR et al. (2008) Sustained modulation of intestinal bacteria by exclusive enteral nutrition used to treat children with Crohn's disease. Aliment Pharmacol Ther 28, 724733.CrossRefGoogle ScholarPubMed
Benus, RF, van der Werf, TS, Welling, GW et al. (2010) Association between Faecalibacterium prausnitzii and dietary fibre in colonic fermentation in healthy human subjects. Br J Nutr 104, 693700.CrossRefGoogle ScholarPubMed
Quince, C, Ijaz, UZ, Loman, N et al. (2015) Extensive modulation of the fecal metagenome in children with Crohn's disease during exclusive enteral nutrition. Am J Gastroenterol 110, 17181729; quiz 1730.CrossRefGoogle ScholarPubMed
Slezak, K, Hanske, L, Loh, G et al. (2013) Increased bacterial putrescine has no impact on gut morphology and physiology in gnotobiotic adolescent mice. Benef Microbes 4, 253266.CrossRefGoogle ScholarPubMed
Tjellstrom, B, Hogberg, L, Stenhammar, L et al. (2012) Effect of exclusive enteral nutrition on gut microflora function in children with Crohn's disease. Scand J Gastroenterol 47, 14541459.CrossRefGoogle ScholarPubMed
Svolos, V, Hansen, R, Nichols, B et al. (2019) Treatment of active Crohn's disease with an ordinary food-based diet that replicates exclusive enteral nutrition. Gastroenterology 156, 13541367 e1356.CrossRefGoogle ScholarPubMed
Ijssennagger, N, van der Meer, R & van Mil, SWC (2016) Sulfide as a mucus barrier-breaker in inflammatory bowel disease? Trends Mol Med 22, 190199.CrossRefGoogle ScholarPubMed
Orel, R & Kamhi Trop, T (2014) Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease. World J Gastroenterol 20, 1150511524.CrossRefGoogle ScholarPubMed
Anderson, JL, Edney, RJ & Whelan, K (2012) Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 36, 503516.CrossRefGoogle ScholarPubMed
Bennet, JD & Brinkman, M (1989) Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet 1, 164.CrossRefGoogle ScholarPubMed
Kunde, S, Pham, A, Bonczyk, S et al. (2013) Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr 56, 597601.CrossRefGoogle Scholar
Suskind, DL, Singh, N, Nielson, H et al. (2015) Fecal microbial transplant via nasogastric tube for active pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 60, 2729.CrossRefGoogle ScholarPubMed
Kump, PK, Grochenig, HP, Lackner, S et al. (2013) Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis 19, 21552165.CrossRefGoogle Scholar
van Nood, E, Vrieze, A, Nieuwdorp, M et al. (2013) Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368, 407415.CrossRefGoogle ScholarPubMed
Moayyedi, P, Surette, MG, Kim, PT et al. (2015) Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149, 102109 e106.CrossRefGoogle Scholar
Rossen, NG, Fuentes, S, van der Spek, MJ et al. (2015) Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 149, 110118 e114.CrossRefGoogle ScholarPubMed
Paramsothy, S, Kamm, MA, Kaakoush, NO et al. (2017) Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 389, 12181228.CrossRefGoogle ScholarPubMed
Costello, SP, Hughes, PA, Waters, O et al. (2019) Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. JAMA 321, 156164.CrossRefGoogle ScholarPubMed
Hold, GL, Smith, M, Grange, C et al. (2014) Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? World J Gastroenterol 20, 11921210.CrossRefGoogle ScholarPubMed

Send article to Kindle

To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Inflammatory bowel disease and the gut microbiota
Available formats

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Inflammatory bowel disease and the gut microbiota
Available formats

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Inflammatory bowel disease and the gut microbiota
Available formats

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *